Take the Diabetes Health Pump Survey
Diabetes Health magazine
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • Eating Well (or at Least Not terribly) at Fast Food Resturants
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
next
Latest
Popular
Top Rated

Latest Insulin Articles

FDA Panelists Vote to Ease Up on Avandia
Ready for a Diabetes Drug Tune-Up?
Juggling More Than Three Pins
How Dottie Kept Her Prediabetes in Check
Type 1 Glucose Production Pill on the Horizon
What are your thoughts on insulin pumps?
Community’s Positive Effect on Diabetes Management
At the Crossroads, I Choose Insulin
Reduced Insulin May Prevent Exercise-Related Hypoglycemia
An Interview With My Husband, Rick
Diabetes Health Reference Charts
Mail Order Reference Guide (PDF)
Syringes Reference Guide (PDF)
Insulin Reference Guide (PDF)
Infusion Sets Reference Guide (PDF)
Mail Order Reference Guide (PDF)
Insulin Pumps Reference Guide (PDF)
Insulin Pen Needles Reference Guide (PDF)
Lancing Devices Reference Guide (PDF)
Lancing Devices Reference Guide (PDF)
See All Charts…
Insulin Archives
Browse the Insulin Archives
Subscribe to the Medications RSS Feed
Print | Email | Share | Comments (2)

Tradjenta, a Drug for Type 2s, Now on U.S. Market


Jul 27, 2011

Lower Blood Glucose levels?

Boehringer Ingelheim and Eli Lilly have begun sales of Tradjenta, a drug for type 2 diabetes, in U.S. pharmacies. The drug (generic name linagliptin) comes in tablet form and is intended to compete with Amylin Pharmaceuticals' Byetta, which is injected, and Merck's Januvia, which also competes with Byetta. Both are well-established in the U.S. market.

Like Januvia, Tradjenta is a DPP-4 inhibitor that blocks an enzyme that interferes with a hormone that stimulates after-meal insulin production. This leads to more insulin in the bloodstream, which lowers blood glucose levels.

The new drug was tested in eight double-blind, placebo-controlled studies that involved 3,800 type 2 patients. It was tested as a standalone therapy and in combination with such standard diabetes drugs as metformin and glimepiride. It is likely that in most cases, Tradjenta will be prescribed as an adjunct to, rather than a replacement for, other drugs.

Despite competing head-to-head against well-established drugs, Tradjenta does bring one competitive advantage to the table: It is taken only once daily and does not pass through the kidneys on the way to excretion. Instead, the drug is expressed through bile and the gut, which makes it safe for patients with kidney problems.

Categories: Blood Glucose, Diabetes, Diabetes, Eli Lilly, Insulin, Pharmacy, Type 2 Issues, Type 2 Medications

Donate to Diabetes Health

You May Also Be Interested In...

Click Here To View Or Post Comments

Comments 2 comments - Jul 27, 2011

©1991-2013 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.